We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.
- Authors
Zoutendijk, Roeland; Hansen, Bettina E; van Vuuren, Anneke J; Boucher, Charles A B; Janssen, Harry L A
- Abstract
Nucleos(t)ide analogues strongly inhibit viral replication in chronic hepatitis B (CHB) infection, but knowledge of their long-term effect on serum hepatitis B surface antigen (HBsAg) levels and HBsAg loss is lacking. Seventy-five CHB patients with virological response (VR) to ETV or TDF were included. HBsAg decline 2 years after VR was most pronounced in HBeAg-positive patients. Age, alanine aminotransferase, and HBeAg loss were associated with HBsAg decline in HBeAg-positive patients. Predicted median time to HBsAg loss was 36 years for HBeAg-positive and 39 years for HBeAg-negative patients. Thus, most patients treated with ETV and TDF will probably need decades of therapy to achieve HBsAg loss.
- Publication
The Journal of infectious diseases, 2011, Vol 204, Issue 3, p415
- ISSN
1537-6613
- Publication type
Journal Article
- DOI
10.1093/infdis/jir282